PTC Therapeutics CEO and leadership

Dr. Peltz founded PTC Therapeutics in 1998 and has served as Chief Executive Officer and a member of the board of directors since the company’s inception. Under his leadership, PTC has grown from a research organization to a publicly traded, global commercial organization with multiple approved products and a foundation of strong technology platforms that continues to drive a robust discovery pipeline for patients with rare disorders. Prior to founding PTC, Dr. Peltz was a Professor in the Department of Molecular Genetics & Microbiology at the Robert Wood Johnson Medical School, Rutgers University. Dr. Peltz is a recognized scientific leader in RNA biology in the area of post-transcriptional control processes involving mRNA turnover and translation, with more than 30 years of research and over 100 publications in this area. Dr. Peltz has received a number of business and scientific awards. Notably, he was elected as a Fellow of the American Academy for the Advancement of Science in 2010. He was recognized as PharmaVoice’s 100 Most Inspiring People in 2009 and received the Dr. Sol J. Barer Award for Vision Innovation and Leadership in 2014. Dr. Peltz received a Ph.D. from the McArdle Laboratory for Cancer Research at the University of Wisconsin.

Mark Boulding has served as Executive Vice President and Chief Legal Officer of PTC Therapeutics, Inc. since March 2012, and previously served as Senior Vice President and General Counsel from April 2002 to February 2012. Prior to joining PTC, Mr. Boulding served as General Counsel, Executive Vice President and Secretary of MedicaLogic/Medscape, Inc., a provider of digital health records software and healthcare information, from May 2000 to April 2002. From June 1999 to May 2000, Mr. Boulding served as the General Counsel, Vice President and Secretary of Medscape, Inc., a provider of online health information and education. Mr. Boulding previously was a partner in two Washington, D.C.-based law firms. Mr. Boulding received a J.D. from the University of Michigan and a B.A. from Yale College.

Eric Pauwels has 35 years of healthcare experience in biopharmaceuticals and medical devices. Eric joined PTC in March 2015 as Senior Vice President and General Manager of the Americas accountable for commercial strategy, global market access. During his tenure at PTC he has been accountable for the organizational build out and launches of Emflaza and Translarna for the treatment of Duchenne Muscular Dystrophy and the launch of Tegsedi for Transthyretin-Related Amyloidosis (h-ATTR) and pre-launch planning of Waylivra for Familial Chylomicronemia Syndrome (FCS) in Latin America. In 2020, Eric was promoted to Chief Business Officer.

From 2011-2015 Eric was with NPS Pharmaceuticals as Chief Commercial Officer and President of International where he built worldwide business operations for the launches of Gattex and Natpara, both biological therapies approved by the FDA and EMA for patients suffering from rare gastrointestinal and endocrine diseases.

In 2005-2010 Eric served as the first Chief Commercial Officer for Shire Rare Disease Business, following the acquisition of TKT where he led the worldwide buildout of Shire Human Genetic Therapies business operations with oversight of 400 employees in 30 countries, a portfolio of 4 rare disease biological treatments and $800Mil in revenues.

Over the course of his career, Eric has launched 25 biopharmaceutical specialty products and orphan drugs in therapeutic areas such as CNS/Neuroscience, cardiovascular, women’s and men’s health, lysosomal storage diseases, hereditary angioedema, short bowel syndrome, hypoparathyroidism, Duchenne muscular dystrophy, transthyretin-related amyloidosis (h-ATTR), familial chylomicronemia syndrome and other genetic disorders.

Previously, Eric held the position of vice president of global strategic marketing for men’s health and cardiovascular diseases at Bayer Healthcare Pharmaceuticals and also held general management functions in the USA, China, France, and Belgium for Fournier Pharma and Johnson & Johnson.

Eric and his family have lived internationally in Europe and China for over 7 years and he is fluent in French.

Mr. Pauwels earned his Bachelor of Science degree from California State Polytechnic University in Pomona, California.

Neil Almstead, Ph.D., has served in several executive positions since joining PTC in 2000 and currently oversees manufacturing and supply chain for the small-molecule and gene-therapy programs. Previously, he was a project manager at Procter & Gamble. Neil has co-authored more than 75 publications and patents in the area of genetic disorders, oncology, and inflammatory diseases. Neil received a B.S. from Clarkson University and a Ph.D. in organic chemistry from the University of Illinois at Urbana-Champaign.

Christine Utter is a Senior VP/Chief Acctg Officer/Head:People Relations at PTC THERAPEUTICS, INC.. She has worked as Assistant Controller at PTC THERAPEUTICS, INC.; Financial Analyst at Engelhard Corporation; and Senior Auditor at EY. Christine attended TCNJ between 1996 and 2000 and College of New Jersey/The.

Dr. Peltz founded PTC Therapeutics in 1998 and has served as Chief Executive Officer and a member of the board of directors since the company’s inception. Under his leadership, PTC has grown from a research organization to a publicly traded, global commercial organization with multiple approved products and a foundation of strong technology platforms that continues to drive a robust discovery pipeline for patients with rare disorders. Prior to founding PTC, Dr. Peltz was a Professor in the Department of Molecular Genetics & Microbiology at the Robert Wood Johnson Medical School, Rutgers University. Dr. Peltz is a recognized scientific leader in RNA biology in the area of post-transcriptional control processes involving mRNA turnover and translation, with more than 30 years of research and over 100 publications in this area. Dr. Peltz has received a number of business and scientific awards. Notably, he was elected as a Fellow of the American Academy for the Advancement of Science in 2010. He was recognized as PharmaVoice’s 100 Most Inspiring People in 2009 and received the Dr. Sol J. Barer Award for Vision Innovation and Leadership in 2014. Dr. Peltz received a Ph.D. from the McArdle Laboratory for Cancer Research at the University of Wisconsin.

Dr. Peltz founded PTC Therapeutics in 1998 and has served as Chief Executive Officer and a member of the board of directors since the company’s inception. Under his leadership, PTC has grown from a research organization to a publicly traded, global commercial organization with multiple approved products and a foundation of strong technology platforms that continues to drive a robust discovery pipeline for patients with rare disorders. Prior to founding PTC, Dr. Peltz was a Professor in the Department of Molecular Genetics & Microbiology at the Robert Wood Johnson Medical School, Rutgers University. Dr. Peltz is a recognized scientific leader in RNA biology in the area of post-transcriptional control processes involving mRNA turnover and translation, with more than 30 years of research and over 100 publications in this area. Dr. Peltz has received a number of business and scientific awards. Notably, he was elected as a Fellow of the American Academy for the Advancement of Science in 2010. He was recognized as PharmaVoice’s 100 Most Inspiring People in 2009 and received the Dr. Sol J. Barer Award for Vision Innovation and Leadership in 2014. Dr. Peltz received a Ph.D. from the McArdle Laboratory for Cancer Research at the University of Wisconsin.